CurveBeam AI Limited (ASX:CVB): How Weight-Bearing CT Imaging Supports Orthopaedic Assessment

Aditi Sarkar

14 October 2026 08:18 PM AEDT

CurveBeam AI Limited (ASX:CVB): How Weight-Bearing CT Imaging Supports Orthopaedic Assessment

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Weight-bearing CT captures three-dimensional anatomy while patients stand under natural load.
HiRise received Chinese regulatory approval in October 2026, enabling commercial sales activities.
The company also develops software that assists with imaging interpretation and orthopaedic workflows.
H1 FY26 revenue reached $4.96 million, with an after-tax loss of $9.85 million.
Equipment adoption, capital availability and regulatory requirements remain relevant operating factors.

CurveBeam AI Limited (ASX:CVB) develops and manufactures specialised point-of-care computed tomography (CT) imaging equipment and associated software for orthopaedic assessment. Its weight-bearing systems image bones and joints while the patient stands, allowing clinicians to evaluate alignment under natural load. During 2026, the company reported product-development activity, financial results and a regulatory approval supporting the introduction of its HiRise system in China.

What Weight-Bearing Imaging Measures

Conventional CT examinations commonly capture anatomy without the patient placing weight on the affected joint. CurveBeam AI Limited (ASX:CVB) offers an alternative imaging configuration in which three-dimensional views can be obtained in a functional standing position. This may reveal differences in joint position, bone relationships or lower-limb alignment that are less apparent when the anatomy is unloaded.

The technology has applications in evaluating the foot, ankle, knee and other musculoskeletal structures. Its clinical value depends on the information required for an individual examination; weight-bearing images do not replace all other diagnostic techniques. Image acquisition, reporting and subsequent decisions remain responsibilities of qualified healthcare professionals.

HiRise and the Role of Imaging Software

CurveBeam AI Limited (ASX:CVB) markets HiRise for three-dimensional imaging of lower-extremity anatomy under physiological load. The system is intended to help clinicians assess joint geometry and support orthopaedic planning. The company also works on software-enabled analysis, including automated segmentation, a process that identifies anatomical structures within a CT scan.

In April 2026, the company described an internal assessment of AI-driven segmentation of cone-beam CT images. Its reported mean surface differences against manually generated comparisons were approximately 0.15–0.29 mm across the protocols assessed. These technical findings concern image processing accuracy and should not be interpreted as proof of improved patient outcomes.

China Approval Changes the Commercial Stage

In October 2026, CurveBeam AI Limited (ASX:CVB) confirmed that China’s National Medical Products Administration had approved HiRise. The approval permits commercial sales of the device in China and advances its collaboration with a local medical-technology partner. The company stated that commercial launch activities, customer engagement and distribution development would follow.

Regulatory authorisation removes a specific market-access requirement, but it does not establish sales volumes, customer demand or a revenue timetable. Commercial delivery still depends on procurement processes, clinical acceptance, training, service arrangements and the practical operation of the distribution network.

Financial Position and Execution Considerations

CurveBeam AI Limited (ASX:CVB) reported H1 FY26 revenue of $4.96 million and a loss from ordinary activities after tax of $9.85 million. Its operating loss was $6.65 million, while cash at the end of the half-year was A$4.02 million. The company also identified cash receivable from existing purchase orders in its February 2026 disclosure.

These figures illustrate the distinction between product demand and profitability. Manufacturing, product development, distribution and regulatory activity can require expenditure before cash is collected from equipment sales. Cash resources, order conversion, installation schedules and expenditure levels therefore remain important in interpreting subsequent company disclosures.

Key Insights

CurveBeam AI Limited (ASX:CVB) combines weight-bearing CT equipment with imaging software for musculoskeletal assessment. The October 2026 Chinese approval is a documented regulatory development, while the company’s half-year accounts show that operating losses and funding requirements remain material. Its commercial performance will be reflected in reported equipment activity, cash flow and financial results rather than regulatory permission alone.

FAQs

Q: What does weight-bearing CT show?

A:It produces three-dimensional images while the patient stands, allowing assessment of bones and joints under load.

Q: What is HiRise?

A:HiRise is CurveBeam AI’s weight-bearing CT system used for orthopaedic imaging.

Q: What changed in China during October 2026?

A:HiRise received NMPA approval, allowing the company and its partner to begin commercial sales activities in China.

Q: Does regulatory approval guarantee revenue?

A:No. Revenue depends on customer orders, installations and commercial execution.

Q: What did CurveBeam AI report for H1 FY26?

A:It reported revenue of $4.96 million and a loss after tax of $9.85 million.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.